# ALGRX 4975 in the Treatment of Patients With Morton's Neuroma

> **NCT00130962** · PHASE2 · COMPLETED · sponsor: **AlgoRx Pharmaceuticals** · enrollment: 60 (—)

## Conditions studied

- Neuroma

## Interventions

- **DRUG:** ALGRX 4975

## Key facts

- **NCT ID:** NCT00130962
- **Lead sponsor:** AlgoRx Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** —
- **Final completion:** 2006-02
- **Target enrollment:** 60 (—)
- **Last updated:** 2005-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00130962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00130962, "ALGRX 4975 in the Treatment of Patients With Morton's Neuroma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00130962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*